EA029290B1 - Новое антитело против ctgf человека - Google Patents

Новое антитело против ctgf человека Download PDF

Info

Publication number
EA029290B1
EA029290B1 EA201491240A EA201491240A EA029290B1 EA 029290 B1 EA029290 B1 EA 029290B1 EA 201491240 A EA201491240 A EA 201491240A EA 201491240 A EA201491240 A EA 201491240A EA 029290 B1 EA029290 B1 EA 029290B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
variable region
amino acid
human
acid sequence
Prior art date
Application number
EA201491240A
Other languages
English (en)
Russian (ru)
Other versions
EA201491240A1 (ru
Inventor
Содзи Ивасаки
Риуити Мория
Масаясу Йосино
Кодзи Такакура
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201491240A1 publication Critical patent/EA201491240A1/ru
Publication of EA029290B1 publication Critical patent/EA029290B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201491240A 2011-12-22 2012-12-21 Новое антитело против ctgf человека EA029290B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Publications (2)

Publication Number Publication Date
EA201491240A1 EA201491240A1 (ru) 2014-11-28
EA029290B1 true EA029290B1 (ru) 2018-03-30

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491240A EA029290B1 (ru) 2011-12-22 2012-12-21 Новое антитело против ctgf человека

Country Status (16)

Country Link
US (1) US9587015B2 (https=)
EP (1) EP2796550B1 (https=)
JP (1) JP6040943B2 (https=)
KR (1) KR20140107507A (https=)
CN (1) CN104011206B (https=)
AR (1) AR089425A1 (https=)
BR (1) BR112014015405A2 (https=)
CA (1) CA2859627A1 (https=)
EA (1) EA029290B1 (https=)
ES (1) ES2665851T3 (https=)
IN (1) IN2014CN04615A (https=)
MX (1) MX345019B (https=)
PL (1) PL2796550T3 (https=)
PT (1) PT2796550T (https=)
TW (1) TW201333034A (https=)
WO (1) WO2013094723A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
CN115925926A (zh) * 2019-06-04 2023-04-07 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用
CN116391041A (zh) * 2020-12-03 2023-07-04 江苏恒瑞医药股份有限公司 一种含抗结缔组织生长因子抗体的药物组合物
JPWO2023238845A1 (https=) 2022-06-07 2023-12-14
TW202434302A (zh) 2022-10-31 2024-09-01 日商安斯泰來製藥股份有限公司 包含類鐸受體７／８雙重促效劑化合物之抗體藥物複合體
TW202502816A (zh) * 2023-03-10 2025-01-16 大陸商上海濟煜醫藥科技有限公司 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP2002532082A (ja) * 1998-12-14 2002-10-02 ユニバーシティー オブ マイアミ 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
JP2004524841A (ja) * 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
WO2007066823A1 (ja) * 2005-12-07 2007-06-14 Nosan Corporation 結合組織増殖因子に対する抗体又はそれを含む組成物
JP2007525194A (ja) * 2003-06-04 2007-09-06 ファイブロジェン，インコーポレイテッド 結合組織成長因子抗体
WO2010053751A1 (en) * 2008-10-29 2010-05-14 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
WO1994020632A1 (fr) 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP2002532082A (ja) * 1998-12-14 2002-10-02 ユニバーシティー オブ マイアミ 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
JP2004524841A (ja) * 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
JP2007525194A (ja) * 2003-06-04 2007-09-06 ファイブロジェン，インコーポレイテッド 結合組織成長因子抗体
WO2007066823A1 (ja) * 2005-12-07 2007-06-14 Nosan Corporation 結合組織増殖因子に対する抗体又はそれを含む組成物
WO2010053751A1 (en) * 2008-10-29 2010-05-14 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor

Also Published As

Publication number Publication date
EP2796550B1 (en) 2018-02-28
EP2796550A1 (en) 2014-10-29
ES2665851T3 (es) 2018-04-27
JPWO2013094723A1 (ja) 2015-04-27
BR112014015405A2 (pt) 2017-06-13
KR20140107507A (ko) 2014-09-04
PT2796550T (pt) 2018-04-18
MX2014007681A (es) 2014-11-25
AR089425A1 (es) 2014-08-20
EA201491240A1 (ru) 2014-11-28
EP2796550A4 (en) 2015-08-19
US9587015B2 (en) 2017-03-07
TW201333034A (zh) 2013-08-16
MX345019B (es) 2017-01-11
CN104011206B (zh) 2017-03-08
JP6040943B2 (ja) 2016-12-07
CN104011206A (zh) 2014-08-27
WO2013094723A1 (ja) 2013-06-27
IN2014CN04615A (https=) 2015-09-18
CA2859627A1 (en) 2013-06-27
US20140343258A1 (en) 2014-11-20
PL2796550T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
JP7538721B2 (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
KR100603899B1 (ko) 인간 ｍｃｐ-1에 대한 항체
EA029290B1 (ru) Новое антитело против ctgf человека
EA022796B1 (ru) Антитело, способное связывать тимусный стромальный лимфопоэтин, нуклеиновая кислота, его кодирующая, экспрессирующий вектор, клетка-хозяин, гибридома, способ получения антитела и его применение
BRPI0113420B1 (pt) Anticorpos para il-1beta humano
US10670604B2 (en) PCSK9 antibody, and pharmaceutical composition and use thereof
JP7415939B2 (ja) 抗ヒトＦｎ１４抗体
KR20120118918A (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
EP3192813A1 (en) Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity
EP0576439B1 (en) Monoclonal antibody against lps core
US5858728A (en) Monoclonal antibody against LPS core
US12583940B2 (en) Monoclonal antibody which targets TFPI
US11976115B2 (en) Antibody binding to human IL-1β, preparation method therefor and use thereof
US20240400658A1 (en) Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
HK40108554A (en) Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
CN117886935A (zh) 抗csf-1r抗体及其应用
CN117164708A (zh) 长效il5纳米抗体及用途
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
CN121378468A (zh) 一种偏肺病毒m蛋白抗体及其应用
HK40046787A (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
EA051720B1 (ru) Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение
JPWO2000027885A1 (ja) 新規キメラポリペプチド

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU